Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?

por Cameron, D A, Anderson, A, Toy, E, Evans, T R J, Le Vay, J H, Kennedy, I C S, Grieve, R J, Perren, T J, Jones, A, Mansi, J, Crown, J, Leonard, R C F
Publicado 2002

Reduced Fractionation in Lung Cancer Patients Treated with Curative-intent Radiotherapy during the COVID-19 Pandemic

por Faivre-Finn, C., Fenwick, J.D., Franks, K.N., Harrow, S., Hatton, M.Q.F., Hiley, C., McAleese, J.J., McDonald, F., O'Hare, J., Peedell, C., Pope, T., Powell, C., Rulach, R., Toy, E.
Publicado 2020

Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK

por Banfill, K., Croxford, W., Fornacon-Wood, I., Wicks, K., Ahmad, S., Britten, A., Carson, C., Dorey, N., Hatton, M., Hiley, C., Thippu Jayaprakash, K., Jegannathen, A., Koh, P., Panakis, N., Peedell, C., Pope, A., Powell, C., Stilwell, C., Thomas, B., Toy, E., Wood, V., Yahya, S., Zhou, S.Y., Price, G., Faivre-Finn, C.
Publicado 2022